Black Rose Inds. Limited — Q4 FY26 earnings call

Call held 22 May 2026

Management summary

Black Rose Industries reported a strong Q4 FY26 with significant revenue and EBITDA growth, driven by operational efficiencies and market share gains. Despite a full-year revenue decline due to chemical price drops and geopolitical challenges, the company maintained profitability and a debt-free balance sheet. Management is focused on new product commercialization, customer expansion, and expects an upward trend in Q1 FY27 revenue due to higher pricing.

Highlights

  • Q4 revenue grew by 38% YoY, demonstrating a strong performance.

  • Q4 EBITDA grew by about 90% YoY, indicating significant operational leverage.

  • Overall FY26 EBITDA margin improved to 11% from 9.7% in the previous year.

  • The company maintained a debt-free status in its operations.

  • A dividend of 125% was declared for the last financial year.

  • Manufacturing segment recorded significant volume growth in acrylamide liquid and NMA.

  • PAM solid project advanced to piloting, with commercialization expected in FY27.

Concerns

  • Overall FY26 revenue declined due to a sustained drop in chemical pricing from the beginning of the year till March 2026.

  • Unpredictable tariff policies by the Trump administration led to weaker offtake from the US oil and gas sector, impacting overall exports.

  • Near-term demand in Q1 FY27 is likely to remain subdued due to global uncertainties.

  • Competition from China continues to impact the acrylamide solid business.

Key financials

4 periods

Headline

  • Dividend Declared
    125%

Q4

  • Revenue Growth
    38%
  • EBITDA Growth
    90%

FY25

  • EBITDA Margin
    9.7%

FY26

  • EBITDA Margin
    11%

What they filed

Q1 FY27: revenue up 48.3%, net profit up 150.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue93 88 82 60 84 −10%75 −15%104 +27%89 +48%
EBITDA7 8 9 6 7 +0%7 −12%13 +44%14 +133%
Net profit10 6 6 4 4 −60%4 −33%9 +50%10 +150%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Manufacturing (FY25)
    35% Revenue Share
  • Distribution (FY25)
    65% Revenue Share
  • Legacy Businesses (FY26)
    1% Revenue Share

Capital allocation

high confidence
  • Debt Gross ₹0 Cr · Net ₹0 Cr · 0.0× EBITDA
    The company continues to remain debt-free in its operations.

Guidance & targets

New Product Commercialization

  • PAM solid project New Product Commercialization · FY27 · Medium confidence commercialization
    The PAM solid project has advanced to the piloting, and we are progressing the project as planned. And we hope to start commercialization activities during this year going forward.

    — Ambarish Daga

New Project Decision

  • Specialty amines project New Project Decision · FY27 · Medium confidence take a decision
    The Specialty amines project, which is being undertaken along with Koei Chemicals Company, that is also progressing as planned, and we hope to take a decision on the project going forward during the current year.

    — Ambarish Daga

Distribution Business

  • New product additions and customer base expansion Distribution Business · FY27 · Medium confidence expanding
    we focus on new product additions during the year and expanding our end-user customer base

    — Ambarish Daga

Revenue

  • Revenue growth Revenue · Q1 FY27 · Medium confidence upwards
    the higher pricing overall should drive the revenue upwards during this quarter.

    — Ambarish Daga

  • Overall top line Revenue · FY27 · Medium confidence increase
    So overall, we see we are targeting an increase in overall top line from the previous year at current market prices.

    — Ambarish Daga

Merchant Exports

  • Performance Merchant Exports · Q1 FY27 · Medium confidence healthy performance
    With merchant exports, we are seeing strong order pipeline and that should turn into a healthy performance during this quarter.

    — Ambarish Daga

Acrylamide Sales

  • Overall sales Acrylamide Sales · Q1 FY27 · Medium confidence well
    The export demand has started to pick up in the second half of the current quarter and that augurs well for our overall sales for acrylamide.

    — Ambarish Daga

Acrylamide Solid Profitability

  • Profitability Acrylamide Solid Profitability · ongoing · Medium confidence supported
    Overall, the profitability should be supported by the operational efficiencies that the company is engaging in continuously.

    — Ambarish Daga

NMA Volumes

  • Volumes NMA Volumes · ongoing · High confidence stable
    Regarding N-methylol acrylamide, (NMA) volumes are expected to remain stable.

    — Ambarish Daga

NMA Growth

  • New customer addition NMA Growth · ongoing · Medium confidence drive growth
    The focus remains on new customer addition to drive growth as NMA continues to be one of the key growth drivers for the company in the manufacturing setup, as of now.

    — Ambarish Daga

What to watch in Q1 FY27

PAM solid project commercialization

FY27
Current Advanced to piloting stage
Target Commercialization

Why it matters

Successful commercialization of the PAM solid project is expected to add to the company's manufacturing basket and offerings.

The PAM solid project has advanced to the piloting, and we are progressing the project as planned. And we hope to start commercialization activities during this year going forward.

Risks & concerns

  • Unpredictable US tariff policies

    high

    Tariff policies by the Trump administration led to weaker offtake from the US oil and gas sector, impacting overall exports.

    Management acknowledged

  • Geopolitical disruptions in the Middle East

    medium

    The crisis in the Middle East impacted the company, though it managed to override it as a reliable supplier.

    Management acknowledged

  • Global uncertainties and subdued demand

    medium

    Near-term demand in Q1 FY27 is likely to remain subdued due to global uncertainties.

    Management acknowledged

  • Competition from China

    medium

    The acrylamide solid business faces competition from China, though volumes remained stable.

    Management acknowledged

  • Raw material price volatility

    medium

    Acrylonitrile prices, a key raw material, shot up drastically in March with the onset of the Middle East war after a period of decline.

    Management acknowledged

Q&A highlights

2 direct, 1 evasive
Q4 margins and EBITDA sustainability Partial
The margins and EBITDA are always a result of the market scenario. It is very difficult to predict the exact margins or EBITDA over a long-term period. Having said that, the company has been focusing on increasing its sales volume as well as profitability, and several initiatives have been taken in this regard.

Addresses investor concern about whether the strong Q4 performance is sustainable or a one-off, with management emphasizing market dynamics and ongoing initiatives.

Asked by Madhur Rathi

Sustainability of ₹13 crore EBITDA per quarter and role of inventory gain Partial
It is not just about having stocks, but we always do maintain sufficient stocks to meet the customer's requirements. So, the margins overall will depend on how the market plays out and how long the situation of the war continues. There is no single factor which will determine the overall margin or EBITDA over the next four quarters.

Clarifies that while inventory management is a factor, overall profitability is influenced by multiple market and geopolitical conditions, not just inventory gains.

Asked by Madhur Rathi

Impact of permanent revocation of plant closure directions Direct
Basically, the permanent revocation means that the closure notice which was received is now permanently revoked, in the sense, the operation can continue without any interruption. So that chapter is now behind us, and we are going to continue operations as per normal.

Confirms the resolution of a significant operational and regulatory risk, ensuring uninterrupted plant operations.

Asked by Vishwendra Singh

Effect of new product additions on top line Direct
In terms of new products being added, as I mentioned, the products are getting added both, in distribution as well as manufacturing. So overall, we see we are targeting an increase in overall top line from the previous year at current market prices.

Provides clarity on the company's growth strategy through product diversification and its expected positive impact on revenue.

Asked by Shweta Agarwal

Target of ₹50 crore EBITDA in FY27 Evasive
It is difficult to put down any number as an assumption because it will not hold much value. There are too many different factors that go into a number. So, I would rather you stay away from giving you any number.

Management explicitly declines to provide specific numerical EBITDA guidance for FY27, citing market uncertainties and multiple influencing factors.

Asked by Madhur Rathi

Capacity increase and revenue growth in FY27/FY28 post plant revocation Partial
So, Mr. Vishwendra, both these things, the revocation and the capacity expansion are not related to each other. So having said that, we hope to achieve the maximum possible utilization for our manufactured products for both the years. And at the same time, as I mentioned, there are projects in the pipeline, which also once commercialized, will add value to the top line.

Clarifies that regulatory clearance is separate from capacity expansion, but reiterates that maximum utilization and new projects will drive future top-line growth.

Asked by Vishwendra Singh

2 min read 5 chapters

Detailed narrative

Q4 and FY26 Financial Performance Overview

Black Rose Industries reported a strong Q4 FY26, with revenue growing by 38% and EBITDA by 90% year-on-year. For the full fiscal year 2026, the overall EBITDA margin improved significantly from 9.7% in the previous year to 11%. Despite these gains, the company's overall revenue for FY26 experienced a minor dip on a standalone basis and declined overall due to a sustained drop in chemical pricing throughout the year. The company maintained its debt-free status and recommended a dividend of 125% for the financial year.

Operational Resilience and Market Strategy

The company's stock and sale model proved highly effective, enabling uninterrupted supply to customers despite geopolitical disruptions in the Middle East, which positively impacted Q4 performance. Black Rose successfully expanded its customer base and market outreach, servicing new geographies and increasing market share. Operational efficiencies and a favorable product mix contributed to improved profitability, offsetting the impact of declining chemical prices and external challenges like unpredictable US tariff policies.

Manufacturing Segment Growth and Product Portfolio

The manufacturing division demonstrated significant volume growth in both acrylamide liquid and NMA during FY26. The acrylamide liquid plant's capacity stands at 32,000 MTPA, with 20,000 MTPA allocated for merchant sales. The company strategically exited the ceramic binder business to focus on higher-value applications and strengthen its upstream acrylamide offerings. The acrylamide solid business maintained stable volumes despite ongoing competition from China.

Outlook and Future Projects

Management anticipates an upward trend in revenue for Q1 FY27, driven by higher pricing and a strong order pipeline in merchant exports. The PAM solid project has advanced to the piloting stage, with commercialization expected within FY27. Additionally, a decision on the Specialty amines project, undertaken with Koei Chemicals Company, is expected during the current year. The company aims to increase its overall top line in FY27 through new product additions and customer base expansion across both distribution and manufacturing segments.

Raw Material and Market Dynamics

Raw material prices, particularly for acrylonitrile, experienced a gradual decline until February 2026 but saw a drastic increase in March due to the Middle East war. Despite this volatility, Black Rose maintained good realization through proactive sales efforts and raw material procurement. Management believes chemical prices have normalized and are expected to remain stable, which should support healthy margins and overall profitability going forward.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls